Genvoya, a new anti-HIV drug that could drastically reduce long-term side effects, was given European Commission approval, allowing 28 countries in the EU to give it to HIV-positive patients. Trials show that Genvoya leads to reduced bone and kidney problems compared to current treatments. Via Buzzfeed News. Posted November 23, 2015.
–Alanna McCatty
